What baseline and follow-up laboratory tests are needed for female-to-male gender-affirming hormone therapy?

Laboratory Monitoring for Female-to-Male Gender-Affirming Hormone Therapy

For transgender men on testosterone therapy, obtain baseline labs including complete blood count, liver function tests, lipid panel, fasting glucose (or HbA1c if diabetic), and testosterone/estradiol levels, then monitor CBC and LFTs every 3 months for the first year, followed by 1-2 times annually thereafter, while checking testosterone levels every 2-3 months until stable in the male physiological range. 1

Baseline Laboratory Assessment

Before initiating testosterone therapy, obtain:

• Complete blood count (CBC) - establishes baseline hemoglobin/hematocrit 1
• Liver function tests (ALT, AST, alkaline phosphatase) - up to 15% of FTM persons develop transient liver enzyme elevations 1
• Lipid panel - testosterone increases cardiovascular risk factors 1
• Fasting blood sugar (if family history of diabetes) or HbA1c (if diabetic) 1
• Testosterone and estradiol levels - establishes pre-treatment baseline 1
• Consider bone mineral density if risk factors present (previous fracture, family history, glucocorticoid use, prolonged hypogonadism) 1

Monitoring During First Year of Therapy

Testosterone Levels (Every 2-3 Months Until Stable)

The target is normal physiological male range (typically 350-700 ng/dL), with timing dependent on formulation 1:

• Testosterone enanthate/cypionate injections: measure midway between injections
• Parenteral testosterone undecanoate: measure just before next injection
• Transdermal testosterone: measure anytime after 1 week
• Oral testosterone undecanoate: measure 3-5 hours after ingestion

Important caveat: During the first 3-9 months, total testosterone may appear falsely elevated due to high SHBG levels in biological females, while free testosterone remains normal 1

Estradiol Monitoring

Measure estradiol during the first 6 months or until uterine bleeding stops for 6 months. Target is <50 pg/mL 1

Hematologic Monitoring

CBC every 3 months for the first year, then 1-2 times annually 1. Testosterone significantly increases hemoglobin and hematocrit - expect increases of approximately 1.0 mg/dL and 3.9% respectively within 6 months 2. Research shows hemoglobin and hematocrit values shift toward male reference ranges after 1 year of therapy 3, 4.

Liver Function Tests

Monitor every 3 months for the first year, then 1-2 times annually 1. While transient elevations occur in up to 15% of patients 1, recent studies show ALT, AST, and ALP may actually increase slightly but remain clinically insignificant 4.

Metabolic Monitoring at Regular Visits

• Weight and blood pressure at each visit 1
• Lipid panel - testosterone therapy decreases HDL cholesterol and may increase triglycerides 4, 5
• Fasting glucose/HbA1c as indicated 1

Long-Term Monitoring (After First Year)

• Clinical evaluation: 1-2 times per year 1
• Testosterone levels: periodically to ensure maintenance in male range
• CBC and LFTs: 1-2 times per year 1
• Cardiovascular risk factor assessment: lipids, blood pressure, glucose 1
• Bone density screening: at age 60 for low-risk individuals, or earlier if non-compliant with hormone therapy 1

Organ-Specific Screening Considerations

• Cervical cancer screening: Annual Pap smear if cervical tissue present 1
• Breast cancer screening: If mastectomy not performed, follow American Cancer Society mammogram guidelines 1

Key Clinical Pitfalls

Hematocrit elevation is the most significant laboratory change - approximately 6.5% of transgender men may develop hematocrit >50% during therapy 2. This typically occurs within the first 6 months and requires dose adjustment or therapeutic phlebotomy.

Reference range interpretation: After 1 year of testosterone therapy, use male reference ranges for hemoglobin, hematocrit, and creatinine 3, 6. Laboratory values shift to resemble the affirmed gender, making transgender-specific reference intervals unnecessary 3.

Cardiovascular risk: While long-term studies show no increased cardiovascular mortality 1, monitor emerging risk factors (lipids, blood pressure, glucose) according to established guidelines 1. The plasma atherogenic index and triglyceride-glucose index may serve as useful early markers 5.